2 Minutes with Joey - LLY Stock News

Avsnitt

• 
  LLY Today - Aug 13: Lawsuits Weigh on Stock 13.08.2026 1min

  Hey there! It’s Joey here, your go-to guy for stock talk. I’ve been in the investing game for a while, and today, we’re looking at Eli Lilly, or LLY for short. Today was a bit of a rough one for them—stock dipped just a tiny bit, down 0.03%. Not a huge drop, but still a red day.So, what’s the deal? Eli Lilly had some news that didn’t sit well with investors. They’ve got ongoing lawsuits related to their obesity drug, Retatrutide, which is causing some worries for folks who are keeping an eye on the stock. People hit the sell button pretty quickly when they heard about it. You know how it goes—lawsuits can freak investors out, and this one seems to be doing just that. Now, on the flip side, there was some chatter about how Eli Lilly is still a strong company, and their market share is looking good. Like, they’re making moves to grab access to new markets, which could mean more customers down the line. But that lawsuit news definitely overshadowed the positives today. And speaking of the competition, Novo Nordisk’s CEO is out there defending their lawsuit against Eli Lilly, saying competition needs to be fair. Seems like there’s a lot of back-and-forth going on in the obesity drug space. It’s wild—these companies are really going at it, trying to stake their claim.One quick thing to keep in mind: Eli Lilly is still being watched closely by analysts, even with the stock slipping a bit. They’re considered one of the top stocks in the IBD 50, so there’s still a lot of interest in how they’ll perform moving forward. Alright, that’s a wrap for today! Just remember, this is all for fun and info—no buy or sell advice here. Thanks for tuning in, and catch you next time!
• 
  LLY Today - Aug 12: Weight Loss Pill Approval 12.08.2026 1min

  Hey there! It’s Joey here, your friendly neighborhood investor, breaking down today’s market action. We’re talking about Eli Lilly, and today was a red day for them, down just about 0.81%. So, what went down? The stock slipped a bit, and it wasn’t a huge surprise. It seems like investors were feeling a little jittery today. There were some mixed signals in the market, and Eli Lilly didn’t exactly stand out among its peers. It’s like they were just kind of there while others were making moves. Now, why’d this happen? Well, part of the chatter was about their weight loss pill snagging its first approval in Europe. That’s a win, right? But instead of rallying off that good news, the stock still took a hit. It looks like broader market pressures, like oil prices dragging things down, played a role too. So, while there’s positive momentum with that approval, it wasn’t enough to keep the stock from getting a little beat up today. Also, there’s been some buzz from analysts after Eli Lilly's recent Q2 earnings call. They had some tough questions, and it seems like investors are still digesting what that all means for the company moving forward. So, yeah, it’s a bit of a mixed bag right now.Looking ahead, Eli Lilly’s got their eyes on growth, especially with their new weight loss pill making waves in Europe. That’s something to keep an eye on as they push for more approvals and market expansions. Alright, that’s a wrap for today! Just remember, I’m here to share info and keep it fun, but this isn’t financial advice. Catch you later, and happy investing!
• 
  LLY Today - Aug 11: Earnings Anticipation 11.08.2026 1min

  Hey there! It’s Joey here, your friendly neighborhood investor. Just hanging out, breaking down the day for you. Today we're talking about Eli Lilly, and it was a bit of a red day for them. The stock dipped about 1%—not huge, but still a bummer.So, what went down? Well, LLY started the day with some solid energy, but as the hours rolled on, it got a bit of a slow bleed. People were probably feeling the jitters ahead of earnings coming up soon. You know how that goes—everyone gets a little anxious when big numbers are about to drop.Now, let’s chat about the why. Analysts have been buzzing about Eli Lilly lately, especially with the whole GLP-1 market thing. There’s been some chatter about how their drugs are really changing the game. Some analysts even bumped up their fair value estimates for the stock. But still, with earnings around the corner, folks are a little cautious, and that makes sense. Nobody wants to get burned if things don’t pan out as expected.And speaking of the horizon, the buzz is that Eli Lilly's next big move could be about a new pill they’re working on. Yeah, they’re not just sticking to injections anymore. That could be a game changer for them, so keep your ears open for updates on that front.Alright, that’s the scoop for today! Just remember, I'm here to keep you informed and entertained, but this isn’t financial advice. Stay curious and keep that investing spirit alive! Catch you later!
• 
  LLY Today - Aug 10: Earnings Buzz and Upgrades 10.08.2026 1min

  Hey there! It's Joey, your friendly investor buddy, here to break down the day for Eli Lilly, or LLY for short. Today was a green day for them, up about 2.14%. Not too shabby!So, what went down? LLY saw a nice little bump in its stock price today. You know how it goes, a lot of chatter around earnings coming up, and people are getting excited. That anticipation can really get the momentum going.Now, let’s talk about why this happened. There’s a lot of buzz surrounding Eli Lilly right now. A few articles are floating around, suggesting that the stock is kind of in a sweet spot. Some folks are saying it’s a buy, while others are just feeling good about its growth potential. Plus, there’s been some chatter about upgrades from analysts, which usually gets investors feeling warm and fuzzy. You know, when the big dogs say nice things, it tends to make people more optimistic. Also, I saw some talk about LLY being part of that elite group of stocks that are just holding strong, like Nvidia and Disney. So, there's definitely some love for Lilly in the air. But hey, it’s not all sunshine and rainbows; some people are wondering if it’s a good time to sell or just hold tight. That uncertainty can make folks hit that sell button pretty fast!On top of that, we’ve got earnings coming up soon, and that’s always a big deal. Investors are looking to see if Eli Lilly can keep up its high growth momentum. It’s like waiting for that big test result, right? Everyone’s on the edge of their seats.So, to wrap it up, Eli Lilly had a solid day, riding the wave of some positive analyst talk and the excitement around their upcoming earnings. Always nice to see a stock on the up and up. Remember, this is just a friendly chat about the stock market, not financial advice. Keep doing your own research, and I’ll catch you later!
• 
  LLY Today - Aug 09: Mixed Signals for Eli Lilly 09.08.2026 1min

  Hey there! It’s Joey here, your friendly neighborhood investor. Let’s break down what went down with Eli Lilly today. Spoiler alert: it was a red day for LLY. It slipped about half a percent. So, here's the scoop: the stock got hit with a little bit of selling pressure today. It opened up, looked promising for a hot minute, but then it kinda fizzled out. We saw some action, but it didn’t really pop like everyone hoped. Now, why the dip? Well, a lot of chatter around the GLP-1 market is stirring things up. There’s buzz about how Eli Lilly stacks up against competitors like Viking Therapeutics. Some folks are weighing their options, and when you see a good competitor in the ring, it can make investors a bit twitchy. Plus, there’s talk about how traders are eyeing the stock after earnings, and it seems like there’s a mixed bag of expectations floating around. So, yeah, that one stung a bit for investors who were hoping for a smoother ride.On a brighter note, Eli Lilly is gearing up for a big FDA filing for Retatrutide. That could be a game changer if all goes well. It’s got potential to shake things up and maybe, just maybe, get some good vibes back into the stock.To wrap it up, LLY had a bit of a rough day, but there are still some exciting things on the horizon. Just remember, I’m here for the info and fun, not to tell you what to do with your money. Stay smart and keep those vibes high! Catch you later!
• 
  LLY Today - Aug 08: Slight Dip Amidst Mixed News 08.08.2026 1min

  Hey there! It’s Joey, your friendly investor here. I’ve been in the game for a while, and today we’re talking about Eli Lilly, or LLY for short. It was a bit of a red day, down just a smidge, like half a percent. Not a huge drop, but still, it got a little smoked.So, what went down? The stock dipped about six bucks, closing around 1185. Not exactly a wild ride, but you know how it goes. Sometimes stocks just sort of chill, and today was one of those days for Lilly. Now, why did this happen? Well, there’s a mix of stuff going on. First off, Truist decided to raise their price target for Lilly, which is usually a good sign, right? But then you had some folks selling off shares, like Rockland Trust Co. unloading over two thousand shares. That can definitely shake things up a bit. Plus, there’s chatter about how the stock's been priced as if it's got two different futures ahead of it. That’s a little confusing, but hey, that’s the market for ya. Now, here’s something to keep on your radar: Eli Lilly's been getting a lot of attention for its incretin products. Those are the drugs that help manage blood sugar levels, and they’re pretty popular. So even if today was a bit slow, their future looks promising.To wrap it up, Eli Lilly had a quiet day, but there’s still a lot of buzz around it. Just remember, I’m here to give you the scoop, not to tell you what to do with your cash. Keep it chill and informed, and I’ll catch you later!
• 
  LLY Today - Aug 07: Eli Lilly's GLP-1 Sales Boost 07.08.2026 1min

  Hey there! It’s Joey, your friendly neighborhood investor. I’ve been around the block a few times, and today I’m breaking down Eli Lilly, or LLY, for August 7th. Spoiler alert: it was a green day, just barely, up 0.05%. So, what went down? Honestly, not a ton of movement. The stock barely budged, but it’s still hanging in there. Volume was steady, which is kind of a good sign that folks are still interested, even if the price didn’t jump through the roof.Now, here’s the juicy part on why it moved a bit. Eli Lilly is riding high on the success of their GLP-1 drugs, which are doing really well. There’s some chatter about how they’re pulling ahead of Novo Nordisk in this space, and that’s got investors feeling a little more optimistic. Plus, Truist just raised their price target, which adds a nice sprinkle of confidence in the mix. People are starting to see Eli Lilly as a solid player in the pharma game, especially with all the buzz around their incretin drugs.And there’s something to keep in mind going forward—earnings reports are coming up. That could shake things up a bit, so keep an ear to the ground on that front.So, that’s the scoop on Eli Lilly today! Just a tiny bump in the road, but hey, every little bit counts, right? Remember, this is just a rundown and not financial advice. Catch you later!
• 
  LLY Today - Aug 06: GLP-1 Sales Boost 06.08.2026 1min

  Hey there! It’s Joey, your friendly neighborhood investor. I’ve been doing this for a while, and today I’m breaking down Eli Lilly, ticker LLY. Spoiler alert: it was a green day, up about 1.7%.So, here’s the scoop. LLY climbed today, and it wasn’t just a small bump. The stock got a nice lift, thanks to some solid news about their GLP-1 drugs. These are the ones that help with weight loss and diabetes, and they’re really starting to take off. Analysts are buzzing about how these sales are widening Lilly's lead over competitors, especially Novo. That’s a big deal, right? Now, why did this happen? Well, a couple of things came into play. First off, there was some fresh data from a conference about their obesity drug, and it looks promising. That got investors feeling good. Plus, analysts were super optimistic, even bumping up their price targets for Lilly after they reported better-than-expected earnings recently. When the pros are excited, it often gets people hitting that buy button.And just a little nugget for you: the buzz around GLP-1 drugs isn’t going anywhere. With more data coming out and the market growing, Lilly seems positioned to keep riding this wave for a bit. So, to wrap it up, Eli Lilly had a solid day thanks to good news about their GLP-1 sales and some analyst love. Always fun to see a stock move in the right direction, right? Just remember, this is all for info and entertainment—no buy or sell advice here. Catch you later!
• 
  LLY Today - Aug 05: Strong Demand for Weight Loss Drugs 05.08.2026 1min

  Hey, what's up? It's Joey here, your friendly investor who's been in the game for a while. So, let’s talk about Eli Lilly today. It was definitely a green day for LLY, up about 4.8%. Not too shabby!So, what happened? Lilly's stock got a nice boost, and honestly, it’s all about those GLP-1 drugs. You know, those weight loss meds everyone’s been buzzing about? They totally crushed sales expectations. Like, blew them out of the water. People are really loving these drugs, and that’s translating into some serious cash for Lilly. Now, why did it jump like this? Well, the company reported some strong second-quarter results, and it looks like the demand for their weight loss meds is just skyrocketing. Analysts were pretty impressed, and when that happens, you know investors start hitting the buy button. Plus, there was some chatter about how this could mean even more growth down the line. I mean, who doesn't want a piece of that action?One thing to keep an eye on is how this GLP-1 trend continues. If demand keeps up like this, Lilly could be in for a wild ride. Just something to think about!Alright, that’s a wrap for today! Just remember, this is all for fun and info—no financial advice here, folks. Catch you later!
• 
  LLY Today - Aug 04: Stock Split Buzz Heating Up 04.08.2026 1min

  Hey there! It’s Joey, your friendly neighborhood investor, here to break down what happened with Eli Lilly today. So, LLY had a pretty chill day, barely moving, just up a smidge at 0.28%. Not exactly a wild ride, but hey, it’s something!Now, let’s talk about why. There’s been a lot of chatter around Eli Lilly lately, especially with their obesity drug making some waves. Folks are starting to wonder if a stock split could be on the horizon. Yeah, that one stung when I heard it, because a split usually gets people hyped! It's like a way to make shares more accessible and can potentially drive more interest from traders. But, not everyone is convinced. Some analysts are saying the stock might be running out of steam, which is a bit of a buzzkill, right? Traders are also eyeing the upcoming earnings report. There’s a lot of speculation about how that’ll shake out, and it’s got people thinking about how much the stock could move after it drops. Everyone loves a little excitement, but it’s a mixed bag of opinions! Some see Eli Lilly as a high-growth momentum leader, while others are just a bit cautious.Oh, and just so you know, they’re gearing up for those earnings soon, so keep your eyes peeled for that. It could be a game-changer, depending on how it goes down.Alright, that’s the scoop on Eli Lilly today. Just remember, I’m here to share info and keep it light – not giving any buy or sell advice. Catch you later!
• 
  LLY Today - Aug 03: FDA Breakthrough for Cancer Therapy 03.08.2026 1min

  Hey there! It’s Joey here, your friendly investor buddy. I’ve been in the game for a while, and today I’m breaking down Eli Lilly, ticker LLY. Spoiler alert: it was a red day for them, down about 2.3%. So, what happened? Well, LLY took a hit today. It got smoked, dropping over 26 bucks. That’s gotta sting, right? But before we get too bummed out, let’s chat about why this happened.Now, here’s the scoop. There was some exciting news earlier in the day. Eli Lilly’s got a second FDA breakthrough designation for their cancer therapy, Olomorasib. That’s a big deal! It means they’re on the fast track for approval, and folks were buzzing about how this could boost their stock to record highs soon. But even with that good news, the stock still took a dive. It seems like the market just wasn’t feeling it today, maybe too much noise from other sectors or investors playing it cautious. Who knows? Sometimes stocks just don’t follow the good news like we expect.And speaking of news, there’s some chatter about merger talks shaking up the big drugmakers in the industry. LLY is getting mixed into that conversation, which might be why some investors are feeling a bit jittery. Change always brings a little uncertainty, you know? One more thing to keep in mind: there’s been a lot of talk lately about the weight loss stock wars, especially between Eli Lilly and Novo Nordisk. Investors are keeping a close eye on both of them, especially with upcoming results that could sway the market. So, to wrap it up, LLY had a rough day despite some promising news with their cancer therapy. It’s a reminder that stocks can be unpredictable, and even good news doesn’t always translate into green. Just keep your eyes peeled on those weight loss metrics and the merger talks. Remember, this is just for fun and info! I’m not your financial advisor, so do your own digging before making any moves. Catch you later!
• 
  LLY Today - Aug 02: Slight dip amid market noise 02.08.2026 1min

  Hey there! It’s Joey here, your friendly neighborhood investor. Today, I'm breaking down what's up with Eli Lilly, and spoiler alert: it was a red day. The stock dipped about half a percent. Not a massive drop, but still, nobody likes seeing red, right?So, here’s what went down. LLY started the day with a bit of energy but faced some selling pressure, which took it down a notch by the close. It kinda felt like a slow bleed, you know? Not the dramatic moves we sometimes see, but still a bummer if you’re holding onto shares.Now, why did it happen? Well, the chatter around the market was pretty mixed. There were some comparisons floating around between Eli Lilly and Abbott Laboratories, which got people thinking about where to put their money. Plus, with all the buzz about Novo Nordisk's struggles, folks are getting a little jittery about the healthcare sector in general. And then you’ve got Jim Cramer weighing in, saying some stocks are more for holding than trading. It’s like a game of musical chairs, and not everyone wants to be left standing when the music stops.One interesting thing to keep an eye on is that Eli Lilly recently hit an all-time high, thanks in part to a boost from CVS coverage for one of their drugs. So, while today wasn’t a big win, there’s some solid momentum behind the scenes that could change the vibe pretty quickly.Alright, that’s the scoop for today! Just remember, this is all for your info and entertainment, not financial advice. Keep your head up, and happy investing!
• 
  LLY Today - Aug 01: Earnings Looming 01.08.2026 1min

  Hey there! It’s Joey, your go-to guy for stock chat, and I've been in the investing game for a while. Today, we’re talking about Eli Lilly, and it was a red day for them, down just a smidge at about half a percent. So, what went down? Eli Lilly’s stock got smoked today, losing a little over six bucks. The volume was pretty average, so nothing too wild there. It seems like investors were feeling a bit cautious. Now, why the dip? Well, a couple of things are swirling around. Earnings reports are coming up soon, and people are getting a little jittery. You know how it goes—when earnings are on the horizon, folks can get a bit skittish, and it’s like they’re waiting for the other shoe to drop. Plus, there’s been chatter about competition heating up in the GLP-1 space, especially with Novo Nordisk making some waves. Their stock's been on a wild ride lately, and that’s got everyone talking about market dynamics. Oh, and speaking of competition, the buzz around new oral GLP-1 medications is growing. That’s something to keep an eye on since it could shake things up in the diabetes and weight-loss med market. To wrap it up, Eli Lilly had a bit of a rough day, but it’s all part of the game. Just remember, this recap is for your info and entertainment, not financial advice. Catch you later!
• 
  LLY Today - Jul 31: Eli Lilly Takes a Dip 31.07.2026 1min

  Hey there! It’s Joey here, your friendly neighborhood investor. I’ve been in the game for a while, and today, we’re chatting about Eli Lilly, ticker LLY. So, it was a bit of a rough day for them, down about 2.8%. Yeah, that one stung a bit.So, what went down? Well, LLY opened up and seemed like it might hang in there, but then it just kinda faded. The stock got smoked as the day went on. Volume was right around the average, so nothing crazy there. Just a slow bleed into the red.Now, why did this happen? It looks like investor vibes were mixed. There’s been chatter about Eli Lilly investing a hefty $750 million to boost their U.S. drug manufacturing, which sounds good, right? But then, they also underperformed compared to some of their competitors, and that can really shake investor confidence. Plus, there’s a bunch of new GLP-1 drugs on the horizon, which could shake up the market. Folks are probably weighing how all these moves fit into the bigger picture. Nobody really knows for sure, but it seems like a combo of excitement and caution.On top of that, Eli Lilly just dropped another $4.5 billion investment in Indiana. That’s a lot of cash, and it shows they’re committed to growth. But in the short term, it might just be too much for some investors to handle right now.So, what’s next? Keep an eye on those new GLP-1 drugs. They’re set to treat more than just obesity, and that could really change the game for Lilly if they play their cards right.Alright, that’s a wrap for today! Just remember, I’m here to share info and keep things fun, but I’m not giving any financial advice or telling you what to do with your money. Catch you later!
• 
  LLY Today - Jul 30: Earnings Report Looms 30.07.2026 1min

  Hey there! It’s Joey, your friendly neighborhood investor, here to break down what went down with Eli Lilly today. So, LLY had a rough day, dropping about 3.8%. Yeah, that one stung.The stock was kind of on a slow bleed through the day. People were hitting that sell button, and it didn’t help that everyone’s eyes are glued to the upcoming earnings report. You know how it goes—everyone gets a bit jittery before earnings, and LLY felt that pressure. Now, why the drop? Well, a couple of articles floating around had some folks worried. One piece from Morningstar was questioning whether LLY is a buy, sell, or just hanging in there. Not exactly the kind of hype you want right before earnings, right? Then there’s this chatter about other stocks that are kicking LLY’s butt lately, with the Motley Fool pointing out that some competitors are really taking the spotlight. It feels like everyone is looking for the next big thing, and LLY’s not the star of the show right now. And let’s not forget the earnings report coming up on August 5. That’s a big deal. Some analysts think the stock could swing around 6.9% based on what gets dropped in that report. So, all eyes are on that—people are either super excited or super nervous about what’s coming next. To wrap it all up, today was a bit of a bummer for Eli Lilly. With earnings around the corner and some tough competition making waves, it's clear the stock's feeling the heat. Just remember, I’m here for the info and the fun, not to give you financial advice. Catch you later!
• 
  LLY Today - Jul 29: Earnings Buzz Looms 29.07.2026 1min

  Hey there! It’s Joey, your friendly longtime investor here, breaking down the day in Eli Lilly. So, LLY had a bit of a down day, slipping just a smidge—like, less than a tenth of a percent. Not a huge deal, but still, it got a little red.So, what went down? Well, the stock barely moved, which can feel kinda boring. But it’s all about what’s coming up. Investors are getting antsy with the earnings report just around the corner on August 5. That’s got people buzzing. You know how it is—everyone’s trying to guess if the numbers will be good or bad. It’s like waiting for a grade on a test you didn’t study for. Some folks are feeling optimistic, while others are kinda holding their breath.Now, why the cautious vibe? A couple of articles popped up talking about how Eli Lilly’s got some weight loss drugs that are making waves, but those aren’t the only things to watch. There’s buzz about their other products too, and people are weighing whether the stock is a buy, sell, or just hanging out in the fair value zone. The chatter’s mixed. Some think it’s a solid play, while others are scratching their heads, wondering if it really diversifies a portfolio. It’s like trying to figure out if you want pizza or tacos for dinner—both are great, but what are you in the mood for?Also, there’s this news about CVS giving a little boost to their Zepbound product, which hit an all-time high recently. That’s definitely something to keep an eye on. It might be a small factor, but hey, sometimes the little things can make a big difference.So yeah, it’s a bit of a waiting game right now. Earnings are coming up, and that’s usually when stocks either soar or take a dive. Just remember, this is all for fun and information, not financial advice. Keep your eyes peeled, and let’s see how it all shakes out! Catch you later!
• 
  LLY Today - Jul 28: Analysts Lift Targets 28.07.2026 1min

  Hey there! It’s Joey here, your friendly neighborhood investor. Let’s talk about Eli Lilly, or LLY for short. Today was a green day for them, up about 2.2%. Not too shabby!So here’s the scoop. LLY started strong and kept that momentum rolling. People are pretty pumped about their prospects, especially after some analysts decided to boost their price targets. They’re looking at Lilly's GLP-1 drugs and thinking, “Yeah, this is gonna be big.” It’s like when your favorite band drops a new album and you just know it’s gonna be a hit.But it’s not all sunshine and rainbows. Goldman Sachs threw some shade, hinting at potential challenges ahead. They’re kind of waving a red flag, saying that the stock might face some headwinds. So, while some folks are hyped, others are a bit cautious. It’s that classic tug-of-war vibe.Now, here’s something interesting on the horizon: Lilly just dropped a cool $4 billion on three vaccine developers. That’s a big move and shows they’re serious about expanding their portfolio. You know, trying to stay ahead in the game. All in all, it’s been a solid day for Eli Lilly, but there’s a mix of excitement and caution in the air. Just remember, this is all for fun and info—no financial advice here! Catch you later!
• 
  LLY Today - Jul 27: Eli Lilly's Mixed Day 27.07.2026 1min

  Hey there! It’s Joey here, your friendly investor buddy, breaking down the day for you. Today, we’re talking about Eli Lilly, and it was a bit of a mixed bag. The stock was up just a smidge, like 0.6% or so. Not exactly a wild ride, but hey, better than being in the red, right?So, what went down today? Well, Eli Lilly had a pretty interesting day in the headlines. They made waves by snagging a psychedelic drug developer for a whopping $3.8 billion. Yeah, you heard that right! That’s a big deal, and it’s got people buzzing about what Eli Lilly is planning next. But amidst all that excitement, the stock has been on a bit of a slow bleed lately. This marks their sixth weekly loss, and folks are starting to wonder if this is just a temporary dip or something more concerning.Now, why the mixed vibes? There’s a lot of chatter out there. Goldman Sachs is kind of waving a red flag, seeing some warning signs for Eli Lilly. Meanwhile, on the flip side, they’re prepping to submit an approval application for their obesity drug, which has been showing some promising results in late-stage trials. So, it’s like they’re juggling good news and some not-so-great signals at the same time.And here’s a little nugget for you: Cathie Wood has been loading up on GLP-1 stocks, which have seen insane growth over the past decade. That could spill over to Eli Lilly, given their involvement in that space. So, there’s definitely some mixed signals floating around.Wrapping things up, Eli Lilly had a pretty chill day, with some solid moves in the background but also some caution from analysts. It’s a wild world out there in the stock market, and Eli Lilly is right in the thick of it. Just remember, I’m here to share what’s happening, not to tell you what to do with your money. Stay informed and have fun with it! Catch you later!
• 
  LLY Today - Jul 26: Buyout Buzz and Drug Approval 26.07.2026 1min

  Hey there! It’s Joey, your friendly longtime investor here to break down the day. Today, we’re talking about Eli Lilly. It was a green day for LLY, up just under 1%. So, what went down? The stock was buzzing a bit, thanks to some big news. Eli Lilly just announced they’re buying out another company for a whopping $2.8 billion. That’s a serious chunk of change! And that’s not all – they’re also gearing up to submit their obesity drug for approval after some solid late-stage trial results. Yeah, that one stung for the competition. Now, why all the excitement? Well, the buyout is getting people hyped about Lilly’s future growth potential. Everyone’s looking at how this could expand their offerings, especially with that obesity drug in the pipeline. Plus, there’s chatter about how some analysts think LLY might actually be undervalued compared to its competitors. That’s got folks feeling optimistic. Just a heads up, there’s a lot of talk about Lilly riding the “peptide wave” in the market. Sounds fancy, right? It’s basically all about their focus on new therapies that could really take off. So, all in all, today was a pretty solid day for Eli Lilly. Remember, I’m just here to share the scoop, not to give any financial advice. Catch you later!
• 
  LLY Today - Jul 25: Riding the Peptide Wave 25.07.2026 1min

  Hey there! It’s Joey, your friendly investor buddy, here to break down what went down with Eli Lilly today. So, LLY had a pretty solid day, up about 0.86%. Not a wild ride, but hey, a win’s a win, right?So, here's the scoop. The stock didn’t move a ton, but it’s still cruising along. There’s been some buzz around Lilly's growth potential, especially with their new obesity treatments. These oral GLP-1 drugs are gaining traction, and people are really excited about it. Like, prescriptions are jumping up, and that’s always a good sign for a company.Now, why all the excitement? Well, a couple of articles pointed out that Lilly might be riding a “peptide wave.” Sounds fancy, huh? Basically, they’re getting a lot of attention for their new treatments, and that’s making investors feel warm and fuzzy. Plus, there’s chatter about their premium valuation being justified because they’re growing so fast. So, folks are feeling optimistic, even if the stock didn’t skyrocket today.Oh, and just so you know, there’s talk about CVS boosting coverage for their drug Zepbound, which could really help Lilly’s sales. That could be a game-changer moving forward!So, to wrap it all up, Eli Lilly had a chill day, but the buzz around their growth story and new treatments is keeping people interested. Just remember, this info is for fun and to keep you in the loop, not financial advice. Catch you later!